Vol. 1 No. 5 (2026), Articles
Vol. 1 No. 5 (2026)

THE ROLE OF SERUM CYSTATIN C IN EARLY ASSESSMENT OF RENEAL RISK IN PATIENTS WITH PREDIABETES

Articles
Published 2026-05-07
Akramjon Chartakov
Andijan State Medical Institute, Assistant of the Department of Hospital Therapy and Endocrinology
PDF

Keywords

prediabetes, cystatin C, chronic kidney disease, biomarkers, risk stratification

How to Cite

Chartakov , A. (2026). THE ROLE OF SERUM CYSTATIN C IN EARLY ASSESSMENT OF RENEAL RISK IN PATIENTS WITH PREDIABETES. GLOBAL SCIENTIFIC CONFERENCE ON MULTIDISCIPLINARY RESEARCH, 1(5), 61-66. https://doi.org/10.5281/zenodo.20074553
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The aim of the study was to evaluate the diagnostic value of serum cystatin C for early renal risk stratification in patients with prediabetes. The study included 55 patients with carbohydrate metabolism disorders and 20 healthy individuals. A significant increase in cystatin C, C-reactive protein, and lipid profile parameters was observed in prediabetic patients compared to controls (p<0.005), while creatinine levels remained within normal limits. Elevated cystatin C was associated with early signs of renal dysfunction. These findings support the use of cystatin C as a sensitive biomarker for detecting subclinical kidney damage in patients with prediabetes.

PDF

References

1. Vart P. et al. National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988-2016 //JAMA network open. – 2020. – Т. 3. – №. 7. – С. e207932-e207932.

2. Plantinga L. C. et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes //Clinical Journal of the American Society of Nephrology. – 2010. – Т. 5. – №. 4. – С. 673-682.

3. Kidney G. Disease: Improving Global Outcomes Diabetes Work,“KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease” //Kidney Int. – 2022. – Т. 102. – С. S1-S127.

4. American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes—2021 //Diabetes Care. – 2021. – Т. 44. – №. Supplement_1. – С. S85-S99.

5. Sallar A., Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: state of the science //Experimental Biology and Medicine. – 2020. – Т. 245. – №. 10. – С. 889-896.

6. Kalaitzidis R. G., Bakris G. L. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? //Current opinion in nephrology and hypertension. – 2009. – Т. 18. – №. 5. – С. 386-391.

7. Kim H. J. et al. Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry //The Korean Journal of Internal Medicine. – 2021. – Т. 36. – №. 5. – С. 1102.

8. Honigberg MC, Zekavat SM, Pirruccello JP, Natarajan P, Vaduganathan M. Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. //J Am Coll Cardiol. 2021 Aug 3;78(5):453-464. doi: 10.1016/j.jacc.2021.05.004.

9. Xiong K, Zhang S, Zhong P, Zhu Z, Chen Y, Huang W, Wang W. Serum cystatin C for risk stratification of prediabetes and diabetes populations. //Diabetes Metab Syndr. 2023 Nov;17(11):102882. doi: 10.1016/j.dsx.2023.102882

10. Sabanayagam C, Wong TY, Xiao J, Shankar A. Serum cystatin C and prediabetes in non-obese US adults. //Eur J Epidemiol. 2013 Apr;28(4):311-6. doi: 10.1007/s10654-013-9781-3

11. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG. Cystatin C identifies chronic kidney disease patients at higher risk for complications.// J Am Soc Nephrol. 2011 Jan;22(1):147-55. doi: 10.1681/ASN.2010050483.